Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Concurrent Mature T-Cell Lymphoma and Myeloma: Is This a Recurrent Association?

M. Christina Cox, Claudia Seimonte, Erica Giacobbi, Gianmario Pasqualone, Livio Pupo, Annagiulia Zizzari, Arianna Guiducci, Luca Franceschini, Manuela Rizzo, Adriano Venditti, Massimiliano Postorino

Blood (2024) 144 (Supplement 1): 6393.

https://doi.org/10.1182/blood-2024-202444

Published: 2024

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Blood (2024) 144 (Supplement 1): 75.

https://doi.org/10.1182/blood-2024-203003

Published: 2024

Journal Articles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Blood (2024) 144 (Supplement 1): 7747.

https://doi.org/10.1182/blood-2024-199041

Published: 2024

Journal Articles

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Blood (2023) 142 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2023-174897

Published: 2023

Journal Articles

Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-137202

Published: 2020

Journal Articles

Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Blood (2020) 136 (Supplement 1): 54–55.

https://doi.org/10.1182/blood-2020-137024

Published: 2020

Journal Articles

Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Blood (2018) 132 (Supplement 1): 4396.

https://doi.org/10.1182/blood-2018-99-113074

Published: 2018

Journal Articles

The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Giovanni Del Poeta, MD, Massimiliano Postorino, MD, Federico Pozzo, PhD, Maria Ilaria Del Principe, MD, Enrico Santinelli, MD, Riccardo Bomben, PhD, Annalisa Biagi, MD, Francesco Buccisano, MD, Francesca Maria Rossi, PhD, Adriano Venditti, MD, Paolo de Fabritiis, MD, Maria Cantonetti, MD, Sergio Amadori, MD, Valter Gattei, MD, William Arcese

Blood (2018) 132 (Supplement 1): 4397.

https://doi.org/10.1182/blood-2018-99-113060

Published: 2018

Journal Articles

Apoptosis Resistance and NOTCH1 Mutations Impair Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib

Giovanni Del Poeta, MD, Maria Ilaria Del Principe, Massimiliano Postorino, Riccardo Bomben, Emilia Iannella, Francesco Buccisano, MD, Maria Francesca Rossi, Adriano Venditti, MD, Enrico Santinelli, Paolo de Fabritiis, Maria Cantonetti, Sergio Amadori, MD, Valter Gattei, MD, William Arcese, MD

Blood (2017) 130 (Supplement 1): 261.

https://doi.org/10.1182/blood.V130.Suppl_1.261.261

Published: 2017

Journal Articles

Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL)

Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Massimiliano Postorino, Michele Dal Bo, Maria Francesca Rossi, Francesco Buccisano, Luca Maurillo, MD, Davide Rossi, Livio Pupo, Benedetta Mariotti, Adriano Venditti, MD, Paolo de Fabritiis, MD, Maria Cantonetti, Gianluca Gaidano, Francesco Lo Coco, MD, Valter Gattei, Sergio Amadori, MD

Blood (2016) 128 (22): 3204.

https://doi.org/10.1182/blood.V128.22.3204.3204

Published: 2016

Journal Articles

Intravenous Administration of Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphomas (PCBCLs): A Retrospective Study

Giovangiacinto Paterno, Annagiulia Zizzari, Daniela Nasso, Lorenzo Tonialini, Cecilia Angeloni, Sara Vaccarini, Massimiliano Postorino, Livio Pupo, Luca Franceschini, Ida Provenzano, Manuela Rizzo, Laura Giannì, Lucia Anemona, Alessandro Mauriello, Giuseppe Alfonso Lombardo, Enrico Scala, Maria Cantonetti, MD

Blood (2014) 124 (21): 5470.

https://doi.org/10.1182/blood.V124.21.5470.5470

Published: 2014

Journal Articles

Use of Plerixafor in Predicted and Proven Poor Mobilizer (according to GITMO criteria). Experience of Policlinico Universitario Tor Vergata

Massimiliano Postorino, Alessandro Lanti, Eleonora Fiorelli, Angelo Salvatore Ferraro, Oana Marilena Chiru, Raffaella Massarelli, Luca Franceschini, Giorgia Guiducci, Ida Provenzano, Livio Pupo, Anna Giulia Zizzari, Gaspare Adorno, Maria Cantonetti, MD, Giancarlo Isacchi, Sergio Amadori

Blood (2012) 120 (21): 4415.

https://doi.org/10.1182/blood.V120.21.4415.4415

Published: 2012

Journal Articles

Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.

Elisabetta Abruzzese, Massimiliano Postorino, md, phd, Tullio Faraggiana, MD, Daniela Renzi, Manuela Rizzo, Micol Quaresima, Livio Pupo, Roberta Cannarsa, Alessandra Spagnoli, Sara Vaccarini, Malgorzata Monika Trawinska, Lucia Anemona, Giuseppe Lombardo, Maria Cantonetti, MD

Blood (2009) 114 (22): 3717.

https://doi.org/10.1182/blood.V114.22.3717.3717

Published: 2009

Journal Articles

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Francesco Buccisano, MD, Luca Maurillo, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Daniela Fraboni, PhD, Emanuele Ammatuna, MD, Maria Irno Consalvo, PhD, Paola Panetta, PhD, Licia Ottaviani, MD, Sabrina Faccia, MD, Manuela Rizzo, MD, Massimiliano Postorino, MD, Maria Cantonetti, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2007) 110 (11): 3498.

https://doi.org/10.1182/blood.V110.11.3498.3498

Published: 2007

Journal Articles

Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.

Francesco Buccisano, MD, Luca Maurillo, MD, Valter Gattei, MD, Giovanni Del Poeta, MD, Maria Ilaria Del Principe, MD, Fraboni Fraboni, Phd, Paola Panetta, Phd, Maria Irno Consalvo, Phd, Selenia Campagna, MD, Laura Giannì, MD, Licia Ottaviani, MD, Massimiliano Postorino, MD, Paolo De Fabritiis, MD, William Arcese, MD, Francesco Lo Coco, MD, Sergio Amadori, MD, Adriano Venditti, MD

Blood (2006) 108 (11): 610.

https://doi.org/10.1182/blood.V108.11.610.610

Published: 2006

Journal Articles

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st Annual Meeting of the American Society of Hematology, December 3-7, 1999, New Orleans, LA.

Adriano Venditti, Francesco Buccisano, Giovanni Del Poeta, Luca Maurillo, Anna Tamburini, Christina Cox, Alessandra Battaglia, Gianfranco Catalano, Beatrice Del Moro, Laura Cudillo, Massimiliano Postorino, Mario Masi, Sergio Amadori

Blood (2000) 96 (12): 3948–3952.

https://doi.org/10.1182/blood.V96.12.3948

Published: 2000

Journal Articles

Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes

Adriano Venditti, Giovanni Del Poeta, Francesco Buccisano, Anna Tamburini, M. Christina Cox, Roberto Stasi, Antonio Bruno, Germano Aronica, Laura Maffei, Giovanna Suppo, Maria Domenica Simone, Laura Forte, Valeria Cordero, Massimiliano Postorino, Vincenza Tufilli, Giancarlo Isacchi, Mario Masi, Giuseppe Papa, Sergio Amadori

Blood (1997) 89 (2): 621–629.

https://doi.org/10.1182/blood.V89.2.621

Published: 1997

NARROW

Concurrent Mature T-Cell Lymphoma and Myeloma: Is This a Recurrent Association?

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

High IGHV Intraclonal Diversification Identifies CLL with Good Prognosis, Features of Anergy and Specific T-Cell Profiles

Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

CD49d Expression Is Included in a Revised 4-Factor Model Predicting Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Multi-Center Real-World Experience

Role of Age, Fitness and Concomitant Medications in CLL Patients Treated with Venetoclax

Do Age, Fitness and Concomitant Medications Influence Management and Outcomes of CLL Patients Treated with Ibrutinib?

Clinical Relevance of NOTCH1 Mutations in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

The Amount of Apoptosis Predicts Outcome in Ibrutinib-Treated Chronic Lymphocytic Leukemia (CLL)

Apoptosis Resistance and NOTCH1 Mutations Impair Clinical Outcome in Chronic Lymphocytic Leukemia (CLL) Patients Treated with Ibrutinib

Low Bax/Bcl-2 Ratio and NOTCH1 Mutations Represent Powerful and Synergistic Adverse Prognostic Factors within Trisomy 12 Chronic Lymphocytic Leukemia (CLL)

Intravenous Administration of Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphomas (PCBCLs): A Retrospective Study

Use of Plerixafor in Predicted and Proven Poor Mobilizer (according to GITMO criteria). Experience of Policlinico Universitario Tor Vergata

Pegylated Liposomal Doxorubicin, Bleomycin, Vinblastine and Dacarbazine (CBVD) in the Treatment of Advanced Primary Cutaneous Lymphomas.

Flow-Cytometric Minimal Residual Disease Determination Is a Surrogate Prognosticator in Adult AML Patients Lacking Specific Molecular Signatures.

Optimal Post-Remission Therapy for Flow-Cytometry Minimal Residual Disease Positive Patients with Acute Myeloid Leukemia.

Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia: Presented in part at the 41st Annual Meeting of the American Society of Hematology, December 3-7, 1999, New Orleans, LA.

Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only